Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Harvard Business School
Chinese Patent Office
Cipla
Federal Trade Commission
Express Scripts
Citi
Argus Health
Chubb
Medtronic

Generated: February 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021071

« Back to Dashboard

NDA 021071 describes AVANDIA, which is a drug marketed by Sb Pharmco and is included in one NDA. It is available from three suppliers. There is one patent protecting this drug. Additional details are available on the AVANDIA profile page.

The generic ingredient in AVANDIA is rosiglitazone maleate. There are twelve drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the rosiglitazone maleate profile page.
Summary for 021071
Tradename:AVANDIA
Applicant:Sb Pharmco
Ingredient:rosiglitazone maleate
Patents:1
Therapeutic Class:Blood Glucose Regulators
Formulation / Manufacturing:see details
Pharmacology for NDA: 021071
Suppliers and Packaging for NDA: 021071
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
AVANDIA rosiglitazone maleate TABLET;ORAL 021071 NDA GlaxoSmithKline LLC 0173-0861 N 0173-0861-18
AVANDIA rosiglitazone maleate TABLET;ORAL 021071 NDA GlaxoSmithKline LLC 0173-0863 N 0173-0863-13

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 2MG BASE
Approval Date:May 25, 1999TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Oct 19, 2020Product Flag?Substance Flag?Delist Request?Y

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 4MG BASE
Approval Date:May 25, 1999TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Oct 19, 2020Product Flag?Substance Flag?Delist Request?Y

Profile for product number 004

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 8MG BASE
Approval Date:May 25, 1999TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Oct 19, 2020Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 021071

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
McKinsey
Harvard Business School
Baxter
Boehringer Ingelheim
Chubb
QuintilesIMS
Julphar
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot